文献速递糖尿病

GLP-1受体激动剂的药物基因组学:基于观察性数据与大型随机对照试验的全基因组分析

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-01-01

本研究纳入4571例接受GLP-1受体激动剂治疗的2型糖尿病成人,来自4个前瞻性观察队列和2项随机临床试验,评估HbA1c降低与基因变异的关联。发现GLP1R的rs6923761G→A(Gly168Ser)及ARRB1低频率变异(主要由rs140226575G→A驱动)与HbA1c降低幅度相关,ARRB1变异携带者血糖降幅更大,作者认为常规基因型可用时携带ARRB1变异者可能从更早启用GLP-1受体激动剂中获益。

要点

  • GLP1R rs6923761G→A每携带一个丝氨酸等位基因,HbA1c降幅减少0.08%(0.9 mmol/mol),p=6.0×10⁻⁵。
  • ARRB1 rs140226575G→A每携带一个甲硫氨酸等位基因,HbA1c降幅增加0.25%(2.7 mmol/mol),p=5.2×10⁻⁶。
  • ARRB1 Thr370Met在西班牙裔及美洲印第安/阿拉斯加原住民中频率(6-11%)高于欧洲白人,效应量相似。

核心结论

  • GLP-1受体激动剂的全基因组药物基因组学研究提供了新的生物学与临床见解。
  • 临床上,当处方时常规可获得基因型时,携带ARRB1变异者可能从更早启用GLP-1受体激动剂中获益。

研究设计与样本

  • 全基因组分析,纳入来自4个前瞻性观察队列(DIRECT、PRIBA、PROMASTER、GoDARTS)和2项随机临床试验(HARMONY 3期和AWARD)的2型糖尿病成人(≥18岁),基线HbA1c≥7%(53 mmol/mol)。
  • 共纳入4571例成人,其中3339例(73%)为欧洲白人,449例(10%)为西班牙裔,312例(7%)为美洲印第安或阿拉斯加原住民,471例(10%)为其他,约2140例(47%)为女性。
  • 主要终点为开始GLP-1受体激动剂后6个月时HbA1c降低幅度;评估GLP1R变异,并进行全基因组关联研究和基于基因的负荷检验。

主要发现

  • GLP1R rs6923761G→A(Gly168Ser)与HbA1c降幅相关:每携带一个丝氨酸等位基因,HbA1c降幅减少0.08%(95%CI 0.04-0.12)或0.9 mmol/mol,p=6.0×10⁻⁵。
  • ARRB1低频率变异与HbA1c降幅相关(最优序列核关联检验p=6.7×10⁻⁸),主要由rs140226575G→A(Thr370Met)驱动:每携带一个甲硫氨酸等位基因,HbA1c降幅增加0.25%(SE 0.06)或2.7 mmol/mol(SE 0.7),p=5.2×10⁻⁶。
  • ARRB1 Thr370Met在西班牙裔及美洲印第安或阿拉斯加原住民中的效应量与欧洲白人相似,该变异在西班牙裔及美洲印第安或阿拉斯加原住民中频率(6-11%)高于欧洲白人。
  • 联合这两个基因可识别出4%的人群,其HbA1c降幅比应答较差的9%人群大30%。

临床怎么用

  • 作者认为,当处方时常规可获得基因型时,携带ARRB1变异者可能从更早启用GLP-1受体激动剂中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the treatment of type 2 diabetes, GLP-1 receptor agonists lower blood glucose concentrations, body weight, and have cardiovascular benefits. The efficacy and side effects of GLP-1 receptor agonists vary between people. Human pharmacogenomic studies of this inter-individual variation can provide both biological insight into drug action and provide biomarkers to inform clinical decision making. We therefore aimed to identify genetic variants associated with glycaemic response to GLP-1 receptor agonist treatment. METHODS: In this genome-wide analysis we included adults (aged ≥18 years) with type 2 diabetes treated with GLP-1 receptor agonists with baseline HbA1c of 7% or more (53 mmol/mol) from four prospective observational cohorts (DIRECT, PRIBA, PROMASTER, and GoDARTS) and two randomised clinical trials (HARMONY phase 3 and AWARD). The primary endpoint was HbA1c reduction at 6 months after starting GLP-1 receptor agonists. We evaluated variants in GLP1R, then did a genome-wide association study and gene-based burden tests. FINDINGS: 4571 adults were included in our analysis, of these, 3339 (73%) were White European, 449 (10%) Hispanic, 312 (7%) American Indian or Alaskan Native, and 471 (10%) were other, and around 2140 (47%) of the participants were women. Variation in HbA1c reduction with GLP-1 receptor agonists treatment was associated with rs6923761G→A (Gly168Ser) in the GLP1R (0·08% [95% CI 0·04-0·12] or 0·9 mmol/mol lower reduction in HbA1c per serine, p=6·0 × 10-5) and low frequency variants in ARRB1 (optimal sequence kernel association test p=6·7 × 10-8), largely driven by rs140226575G→A (Thr370Met; 0·25% [SE 0·06] or 2·7 mmol/mol [SE 0·7] greater HbA1c reduction per methionine, p=5·2 × 10-6). A similar effect size for the ARRB1 Thr370Met was seen in Hispanic and American Indian or Alaska Native populations who have a higher frequency of this variant (6-11%) than in White European populations. Combining these two genes identified 4% of the population who had a 30% greater reduction in HbA1c than the 9% of the population with the worse response. INTERPRETATION: This genome-wide pharmacogenomic study of GLP-1 receptor agonists provides novel biological and clinical insights. Clinically, when genotype is routinely available at the point of prescribing, individuals with ARRB1 variants might benefit from earlier initiation of GLP-1 receptor agonists. FUNDING: Innovative Medicines Initiative and the Wellcome Trust.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Dawed AY, Mari A, Brown A, et al. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 2023. PMID: 36528349. doi:10.1016/S2213-8587(22)00340-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。